Sevoflurane and Dexmedetomidine's Contrasting Renal Impacts After Non-Cardiac Surgery

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

March 30, 2024

Conditions
AKI - Acute Kidney Injury
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine (Precedex, 100 µg/ml; Rewine Pharmaceutical; Varachha, Seurat, Gujarat) was administered before induction of anesthesia in the form of a 1 µg/kg; loading dose. The loading dose was diluted with 10 ml of normal saline and injected slowly for 10 minutes. IO infusion was prepared to provide 0.2-0.7 µg/kg/h, initially the lowest possible dose was infused and was increased gradually to control IO stress reflexes but with MAP, and HR monitoring to guard against IO hypotension and bradycardia. PO infusion was prepared to provide DXM in a dose of 0.15 µg/kg/h for 24-h. Placebo 0.9% saline solution was provided to patients of the SEVO group at a similar rate and duration.

DRUG

Sevoflurane inhalant product

Anesthesia was induced by fentanyl 1 μg/kg/min, propofol 1.5-2 mg/kg and rocuronium 0.5 mg/kg, then tracheal intubation was aided by gentle tracheal pressure and an endotracheal tube of appropriate size was inserted with the aid of fiberoptic laryngoscopy and patients were mechanically ventilated to keep ETCO2 in the range of 30-35 mmHg. Anesthesia was maintained for patients of both groups by sevoflurane 2% in oxygen 100% and rocuronium (0.15 mg/ kg) according to the requirements.

Trial Locations (1)

13511

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06835010 - Sevoflurane and Dexmedetomidine's Contrasting Renal Impacts After Non-Cardiac Surgery | Biotech Hunter | Biotech Hunter